Genta Stops Active Marketing Of Ganite
This article was originally published in The Pink Sheet Daily
Executive Summary
Genta stops actively marketing its cancer-related hypercalcemia treatment Ganite as part of company restructuring
You may also be interested in...
Genta, Aventis Halt Genasense Expanded Access Program
The Aventis-managed program was terminated following an FDA advisory committee’s negative review of the melanoma therapy and withdrawal of the NDA.
Genta, Aventis Halt Genasense Expanded Access Program
The Aventis-managed program was terminated following an FDA advisory committee’s negative review of the melanoma therapy and withdrawal of the NDA.
Genta Withdraws NDA For Genasense In Melanoma
The company has requested a meeting with FDA to identify the next steps for further development. The move coincides with a restructuring at Genta to focus resources on the Genasense program.